ERBB2 and breast carcinoma: An alternative approach, PASylation—the addition of Pro, Ala, and Ser sequences—has been tested in pilot mice models by Mendler et al. [65] and in a human study (n = 1) with HER2-positive breast cancer by Richter et al. [66].